In clinical practice, the developed HER2‐morphometric signature is a robust tool that could be used as a prognostic and a predictive indicator of HER2 oncogenic signalling activity, aggressive tumour behaviour and hence the response to HER2 pathway targeting therapy. The gene discussed is ERBB2; the disease is neoplasm.